Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
复制标题
DOI：
10.1016/s0140-6736(19)32135-x
复制
发表时间：
2019-10-26
期刊：
影响因子：
168.9
通讯作者：
Williams, Bryan
中科院分区：
文献类型：
--
作者：
Agarwal, Rajiv;Rossignol, Patrick;Williams, Bryan
背景：螺内酯可有效降低未控制的顽固性高血压患者的血压。然而，慢性肾脏疾病患者使用螺内酯可能会受到高钾血症的限制。我们评估了在慢性肾病和顽固性高血压患者中，使用钾结合剂来允许更持久地使用螺内酯。在这项多中心、随机、双盲、安慰剂对照的2期研究中，我们招募了年龄在18岁及以上的慢性肾脏疾病患者（估计肾小球滤过率为25 - 25）
Background Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluated use of the potassium binder patiromer to allow more persistent use of spironolactone in patients with chronic kidney disease and resistant hypertension.Methods In this phase 2 multicentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged 18 years and older with chronic kidney disease (estimated glomerular filtration rate 25 to